Atara Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net income (loss) | $38,010 | $(31,752) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,209 | 8,397 |
| Depreciation and amortization expense | 1,795 | 1,391 |
| Accretion of liability related to sale of future revenues | 852 | 1,046 |
| Amortization (accretion) of investment premiums (discounts) | 259 | 37 |
| Non-cash operating lease expense | 3,950 | 2,954 |
| Loss on impairment of lease right-of-use asset | 4,130 | — |
| Other non-cash items, net | 770 | 48 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (7,393) | (1,726) |
| Inventories | 10,655 | (6,378) |
| Other current assets | 4,535 | (2,061) |
| Other assets | 8 | 443 |
| Accounts payable | (2,983) | (826) |
| Accrued compensation | (1,990) | (5,812) |
| Accrued research and development expenses | (6,201) | (1,436) |
| Other current liabilities | 3,493 | (742) |
| Deferred revenue | (79,109) | 8,478 |
| Operating lease liabilities | (3,238) | (1,673) |
| Other long-term liabilities | 110 | — |
| Net cash used in operating activities | (28,138) | (29,612) |
| Investing activities | ||
| Proceeds from maturities and sales of short-term investments | 17,199 | 14,844 |
| Purchases of property and equipment | — | (127) |
| Net cash provided by investing activities | 17,199 | 14,717 |
| Financing activities | ||
| Proceeds from sale of pre-funded warrants to purchase common stock in a registered direct offering, net | — | 15,000 |
| Proceeds from issuance of common stock through ATM facilities, net | — | 9,374 |
| Taxes paid related to net share settlement of restricted stock units | — | (6) |
| Principal payments on finance lease obligations | (250) | (227) |
| Net cash provided by (used in) financing activities | (250) | 24,141 |
| Increase (decrease) in cash, cash equivalents and restricted cash | (11,189) | 9,246 |
| Cash, cash equivalents and restricted cash at beginning of period | 25,176 | 25,987 |
| Cash, cash equivalents and restricted cash at end of period | $13,987 | $35,233 |
| Non-cash investing and financing activities | ||
| Property and equipment purchases included in accounts payable and other accrued liabilities | $— | $— |
| Accrued costs related to underwritten public offering | $— | $177 |
| Accrued costs related to ATM facility | $— | $26 |
| Supplemental cash flow disclosure | ||
| Cash paid for interest | $66 | $114 |
| Cash paid for income taxes | $— | $24 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.